

# Index

- 24-hr oesophageal and intragastric pH, 455  
5-aminosalicylates, 179  
5-HT1 receptor agonism, 805  
6-mercaptopurine, 679  
6-thioguanine nucleotides, 1269  
6-tioguanine, 1269  
90 years, 1153
- Abraha, H. *see* Pereira, S.P.  
Abraham, N.S., Moayyedi, P., Daniels, B. & Veldhuyzen Van Zanten, S.J.O. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia, 631  
Achem, S.R. *see* Ward, E.M.  
*Acid Suppression*, 591, 655  
*Acidity index*, 443  
Adam, V. *see* Barkun, A.N.  
Adefovir, 25  
*Adverse drug reaction*, 303  
*Ageing*, 39  
Aguirre, T. *see* El-Serag, H.B.  
Aichbichler, B.W. *see* Wenzl, H.H.  
Aithal, G.P., Haugk, B., Das, S., Card, T., Burt, A.D. & Record, C.O. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? 391  
Alahuddin, S. *see* Kaptan, K.  
Alahuddin, S. *see* Rajendra, S.  
Albanese, A. *see* Brisinda, G.  
*Alicaforse*, 281  
*Aloe vera*, 739  
*Amantadine*, 339  
Ammon, S. *see* Treiber, G.  
Amoruso, A. *see* De Francesco, V.  
*Anal fissure*, 481  
Andreyev, H.J.N. *see* Lindsay, J.O.  
Andrieux, C. *see* Bouhnik, Y.  
Andriulli, A. *see* Mangia, A.  
Angelico, F. *see* Angelico, M.  
Angelico, M., Cepparulo, M., Angelico, F., Franciosi, S., Barlattani, A., Di Candilo, F., Della Vecchia, R., Demelia, L., De Sanctis, G., Gentile, S., Grieco, A., Parruti, G., Sabusco, G., Tarquini, L., Tosti, A. & Zaru, S. The SMIEC 1 Group. A randomized controlled trial of amantadine plus interferon- $\alpha$ 2a vs. interferon- $\alpha$ 2a alone in naïve patients with chronic hepatitis C randomized according to the early virological response to interferon- $\alpha$ 2a monotherapy, 339  
Annibale, B. *see* Panzuto, F.  
*Antibiotic*, 789  
*Antibiotic resistance*, 1009, 1315  
*Antibiotic treatment*, 1315  
*Antidopaminergic prokinetics*, 379
- Antisense*, 281  
*Antro-pyloro-duodenal motility*, 805  
*APC gene*, 1225  
Apolinario, A., Diago, M., Lo Iacono, O., Lorente, R., Pérez, C., Majano, P.L., Clemente, G. & García-Monzón, C. Increased circulating and intrahepatocellular T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy, 551  
*Apoptosis*, 1225  
*Appropriateness*, 197  
Arden, N.K. *see* Treble, T.M.  
Arguedas, M.R. *see* Raines, D.L.  
Armstrong, D. *see* Chiba, N.  
Armstrong, D. *see* Stanghellini, V.  
Armuzzi, A. *see* Candelli, M.  
*Arterial embolization*, 999, 1301  
*Asacol*, 1089  
*Aspirin*, 39, 359, 1099  
*Atrophic gastritis*, 107  
Austin, A.S., Mahida, Y.R., Clarke, D., Ryder, S.D. & Freeman, J.G. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis, 79  
*Autoimmune liver diseases*, 209  
Axon, A.T.R. Personal view: to treat or not to treat? *Helicobacter pylori* and gastro-oesophageal reflux disease – an alternative hypothesis, 253  
*Azathioprine*, 295, 679, 1147
- Baccini, F. *see* Panzuto, F.  
*BAclofen*, 1041  
*Bacterial virulence factors*, 219  
Baier, P. *see* Büning, C.  
Bailey, D.M. *see* Kitiyakara, T.  
Baird, A.W. *see* O'Keeffe, C.  
*Balsalazide*, 1089  
Bane, B. *see* Miner Jr, P.  
Bardhan, K.D. *see* Stanghellini, V.  
Bardou, M. *see* Barkun, A.N.  
Barkun, A. *see* Chiba, N.  
Barkun, A.N., Herba, K., Adam, V., Kennedy, W., Fallone, C.A. & Bardou, M. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis, 591  
Barlattani, A. *see* Angelico, M.  
Barone, M. *see* De Francesco, V.  
Bautista, J., Fullerton, H., Briseno, M., Cui, H. & Fass, R. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain – a randomized, double-blind, placebo-controlled, crossover trial, 1123

- Belaiche, J. *see* Louis, E.  
 Benazzato, L. *see* Di Sabatino, A.  
 Benöhr, P. *see* Raddatz, D.  
 Benson, M.J. *see* Kang, J.Y.  
 Bentivoglio, A.R. *see* Brisinda, G.  
 Berloco, P. *see* De Francesco, V.  
 Bernstein, C.N. & Leslie, W.D. Review article: osteoporosis and inflammatory bowel disease, 941  
 Beyan, C. *see* Kaptan, K.  
 Biancone, L., Tosti, C., Geremia, A., Fina, D., Petruzzello, C., Emerenziani, S. & Pallone, F. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial, 755  
*Bifidobacterium*, 889  
 Bikerk, C.J., Muris, J.W.M., Knottnerus, J.A., Hoes, A.W. & De Wit, N.J. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome, 245  
 Billardi, C. *see* Zentilin, P.  
*Biliary disorders*, 209, 563, 601, 901, 1153, 1293  
 Binder, V. *see* Jess, T.  
*Biofeedback*, 829  
*Biological therapy*, 749  
*Biomarker*, 797  
 Björkman, D. *see* Loftus Jr, E.V.  
*Bleeding*, 1051  
 Blonska-Fajrowska, B. *see* Mangel, A.W.  
 Bloom, S., Kiilerich, S., Lassen, M.R., Forbes, A., Leiper, K., Langholz, E., Irvine, E.J., O'Morain, C., Lowson, D. & Orm, S. Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis, 871  
 Blumenstein, I. *see* Schröder, O.  
 Bochow, B. *see* Büning, C.  
 Bockemühl, M. *see* Raddatz, D.  
*Bone*, 1063  
*Bone biochemical markers*, 563  
*Bone densitometry*, 563  
 Borrelli, F., Capasso, R., Russo, A. & Ernst, E. Systematic review: green tea and gastrointestinal cancer risk, 497  
*Botulinum toxin*, 695  
 Bouhnik, Y., Neut, C., Raskine, L., Michel, C., Riottot, M., Andrieux, C., Guillemot, F., Dyard, F. & Flourié, B. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation, 889  
 Bouras, E.P. *see* Ward, E.M.  
 Bradley, J. *see* Miner Jr, P.  
 Bramble, M.G. *see* Panter, S.J.  
 Branca, G. *see* Cammarota, G.  
 Brandara, F. *see* Brisinda, G.  
 Briseno, M. *see* Bautista, J.  
 Brisinda, G., Albanese, A., Cadeddu, F., Bentivoglio, A.R., Mabisombi, A., Marniga, G. & Maria, G. Botulinum neurotoxin to treat chronic anal fissure: results of a randomized 'Botox vs. Dysport' controlled trial, 695  
 Brisinda, G., Cadeddu, F., Brandara, F., Maria, G., Halphen, M., Chaussade, S., Minić, M., Guslandi, M., Cheung, O. & Wald, A. Letters to the editors, 1131  
 Bruley Des Varannes, S. *see* Galmiche, J.P.  
 Bruley des Varannes, S. *see* Zerbib, F.  
 Brune, K. *see* Dormann, H.  
 Buch, A. *see* Sandborn, W.J.  
 Bueno De Mesquita, M. *see* Marchal, L.  
 Büchner, S. *see* Büning, C.  
 Büning, C., Genschel, J., Büchner, S., Krüger, S., Kling, K., Dignass, A., Baier, P., Bochow, B., Ockenga, J., Schmidt, H.H.-J. & Lochs, H. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation, 1073  
 Burattini, O. *see* De Francesco, V.  
 Burggraaf, J. *see* Kamerling, I.M.C.  
 Burt, A.D. *see* Aithal, G.P.  
 Buxton-Thomas, M. *see* Pereira, S.P.  
 Cadeddu, F. *see* Brisinda, G.  
*CagA*, 407  
 Calder, P.C. *see* Trebble, T.M.  
 Calvert, E.L., Whorwell, P.J. & Houghton, L.A. Inter-digestive and post-prandial antro-pyloro-duodenal motor activity in humans: effect of 5-hydroxytryptamine 1 receptor agonism, 805  
 Calvet, X. *see* Gisbert, J.P.  
*Camellia sinensis*, 497  
 Camilleri, M. *see* Cremonini, F.  
 Cammarota, G., Martino, A., Pirozzi, G., Cianci, R., Branca, G., Nista, E.C., Cazzato, A., Cannizzaro, O., Miele, L., Grieco, A., Gasbarrini, A. & Gasbarrini, G. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for *Helicobacter pylori* infection, 789  
*Cancer*, 879  
 Candelli, M. *see* Santarelli, L.  
 Candelli, M., Armuzzi, A., Nista, E.C., Fini, L., Gasbarrini, G. & Gasbarrini, A. Letter to the Editors, 243  
 Cannizzaro, O. *see* Cammarota, G.  
 Capasso, R. *see* Borrelli, F.  
 Caprai, S. *see* Sciveres, M.  
*Capsaicin*, 415  
 Capurso, G. *see* Panzuto, F.  
 Carballo, F. *see* Gisbert, J.P.  
 Card, T. *see* Aithal, G.P.  
*CARD15*, 1073  
*Case-control study*, 817  
 Cash, B.D. & Chey, W.D. Review article: irritable bowel syndrome – an evidence-based approach to diagnosis, 1235  
 Castell, D.O. *see* Tutuian, R.  
 Castle, M.Z.D., Silk, D.B.A. & Libby, G.W. Review article: the rationale for antidepressant therapy in functional gastrointestinal disorders, 969  
 Cazzato, A. *see* Cammarota, G.  
*CCK*, 601  
*Celiac disease*, 1199  
 Ceppa, P. *see* Zentilin, P.  
 Cepparulo, M. *see* Angelico, M.  
 Chan, A.O. *see* Hui, C.-K.  
 Chan, A.O.O. *see* Lam, C.-M.

- Chan, A.O.O. *see* Wong, W.M.  
 Chan, A.O.O., Yuen, M.F., Lam, C.M., Fong, C.Y., Wong, B.C.Y. & Lai, C.L. Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong, 401  
 Chan, F.K.L. & Graham, D.Y. Review article: prevention of non-steroidal antiinflammatory drug gastrointestinal complications – review and recommendations based on risk assessment, 1051  
 Chan, H.L.-Y. *see* Wong, V.W.-S.  
 Chan, S.-C. *see* Hui, C.-K.  
 Chang, C.-M. *see* Ng, F.-H.  
 Chang, F.-Y. *see* Huo, T.  
 Chang, F.-Y. *see* Huo, T.-I.  
 Chang, L. *see* Schwetz, I.  
 Charles, F. *see* Zerbib, F.  
 Chaussade, S. *see* Brisinda, G.  
 Chayama, K. *see* Kai, H.  
*Chelators*, 157  
*Chemokines*, 551  
*Chemoprotective substance*, 497  
 Chen, H.X. *see* Xiong, L.S.  
 Chen, M.H. *see* Xiong, L.S.  
 Chen, S.C. & Rex, D.K. Review article: registered nurse-administered propofol sedation for endoscopy, 147  
 Chen, W.-H. *see* Ng, F.-H.  
 Cheung, O. *see* Brisinda, G.  
 Cheung, O. & Wald, A. Review article: the management of pelvic floor disorders, 481  
 Cheung, W.W. *see* Hui, C.-K.  
 Chey, W.D. *see* Cash, B.D.  
 Chiang, J.-H. *see* Huo, T.  
 Chiang, J.-H. *see* Huo, T.-I.  
 Chiba, N., Veldhuyzen Van Zanten, S.J.O., Escobedo, S., Grace, E., Lee, J., Sinclair, P., Barkun, A., Armstrong, D. & Thomson, A.B.R. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of *H. pylori*-positive primary care patients with uninvestigated dyspepsia, 349  
 Chinn, D.J. *see* Rubin, G.P.  
 Chiu, Y.-L. *see* Freston, J.W.  
*Cholecystokinin*, 1261  
*Cholestasis*, 1293  
*Chronic hepatitis B*, 25  
*Chronic hepatitis C*, 339  
*Chronic Intestinal Pseudo-Obstruction*, 687  
*Chronic liver disease*, 715  
*Chronic viral hepatitis B*, 323  
 Cianci, R. *see* Cammarota, G.  
 Ciccioppo, R. *see* Di Sabatino, A.  
 Cipollina, L. *see* Tonini, M.  
*Cirrhosis*, 391, 1159  
*Clarithromycin*, 993, 1009  
 Clarke, D. *see* Austin, A.S.  
 Clemente, G. *see* Apolinario, A.  
*Clinical alert*, 303  
*Clopidogrel*, 359  
*Cluster analysis*, 133  
*Coeliac disease*, 1277  
 Cohen, A.F. *see* Kamerling, I.M.C.  
*Cohort study*, 679  
*Colitis*, 167, 871  
 Collin, P., Thorell, L., Kaukinen, K. & Mäki, M. The safe threshold for gluten contamination in gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? 1277  
 Colombel, J.-F. *see* Louis, E.  
*Colon*, 765  
*Colonic diverticular disease*, 765  
*Colonoscopy*, 765  
*Colorectal cancer*, 1, 287  
 Colquhoun, S. *see* Firpi, R.J.  
*Complementary therapy*, 521  
*Complications*, 1051  
*Computer assisted signal processing*, 303  
*Congenital abnormalities*, 679  
*Constipation*, 481, 889  
*Copper*, 157  
 Corazza, G.R. *see* Di Sabatino, A.  
 Corazza, G.R. *see* Tonini, M.  
*Cost analysis*, 349  
*Cost-benefit analysis*, 1247  
*Cost-effectiveness*, 349, 591  
*Cost-effectiveness analysis*, 571, 1199  
 Cotler, S.J. *see* Jensen, D.M.  
 Courtney, E.D.J., Melville, D.M. & Leicester, R.J. Review article: chemoprevention of colorectal cancer, 1  
*COX-2 inhibitors*, 197, 1051  
*COX-2 selective inhibitors*, 817  
 Crema, F. *see* Tonini, M.  
 Cremonini, F. *see* Santarelli, L.  
 Criegee-Rieck, M. *see* Dormann, H.  
*Crohn's disease*, 287, 295, 427, 511, 671, 953, 1019, 1073, 1147, 1269  
 Cui, H. *see* Bautista, J.  
*Culture-guided*, 789  
*Cyclosporin A*, 209  
*CYP2C19*, 113  
*Cytokine(s)*, 671, 1063  
*D2 receptor blockade*, 379  
 Dagpal, K. *see* Uygun, A.  
 Dahlerup, J.F. *see* Vilien, M.  
 Dall'Ozzo, S. *see* Louis, E.  
 D'Ambra, G. *see* Panzuto, F.  
 Dammann, H.-G., Saleki, M., Torz, M., Schulz, H.-U., Krupp, S., Schürer, M., Timm, J. & Gessner, U. Effects of buffered and plain acetylsalicylic acid formulations with and without ascorbic acid on gastric mucosa in healthy subjects 367  
 Daniels, B. *see* Abraham, N.S.  
 Das, S. *see* Aithal, G.P.  
 Davis, D.M. *see* Ward, E.M.  
 Davis, K.J. *see* Higgins, P.D.R.

- De Francesco, V., Della Valle, N., Stoppino, V., Amoruso, A., Muscatiello, N., Panella, C. & Ierardi, E. Effectiveness and pharmaceutical cost of sequential treatment for *Helicobacter pylori* in patients with non-ulcer dyspepsia, 993
- De Francesco, V., Zullo, A., Margiotta, M., Marangi, S., Burattini, O., Berloco, P., Russo, F., Barone, M., Di Leo, A., Minenna, M.F., Stoppino, V., Morini, S., Panella, C., Francavilla, A. & Ierardi, E. Sequential treatment for *Helicobacter pylori* does not share the risk factors of triple therapy failure, 407
- De Kam, M.L. *see* Kamerling, I.M.C.
- De Ponti, F. *see* Tonini, M.
- De Sanctis, G. *see* Angelico, M.
- De Silva, A. *see* Langmead, L.
- De Vos, M. *see* Louis, E.
- De Wit, N.J. *see* Bijkerk, C.J.
- Decision analysis*, 1247
- Deibert, P. *see* Herrlinger, K.R.
- Delayed diagnosis*, 981
- Delgado-Aros, S. *see* Cremonini, F.
- Della Valle, N. *see* De Francesco, V.
- Della Vecchia, R. *see* Angelico, M.
- Delle Fave, G. *see* Panzuto, F.
- Demarchi, B., Vos R., Deprez P., Janssens J., Tack J. Influence of a lipase inhibitor on gastric sensitivity and accommodation to an orally ingested meal, 1261
- Demelia, L. *see* Angelico, M.
- Deprez, P. *see* Demarchi, B.
- Devault, K.R. *see* Ward, E.M.
- Deveci, S. *see* Uygun, A.
- Developing country*, 1315
- D'Haens, G. *see* Marchal, L.
- Dhar, A. *see* Kang, J.Y.
- D'Hoore, A. *see* Marchal, L.
- Di Candilo, F. *see* Angelico, M.
- Di Caro, S., Delgado-Aros, S., Sepulveda, A., Gasbarrini, G., Gasbarrini, A. & Camilleri, M. Notice of retraction of article. Meta-analysis: the relationship between *Helicobacter pylori* infection and gastro-oesophageal reflux disease, 145
- Di Caro, S. *see* Cremonini, F.
- Di Giulio, E. *see* Panzuto, F.
- Di Leo, A. *see* De Francesco, V.
- Di Sabatino, A., Cicciocipri, R., Benazzato, L., Sturniolo, G.C. & Corazza, G.R. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients, 1019
- Diagnosis*, 157, 829, 923
- Diago, M. *see* Apolinario, A.
- Diaz-Rubio, M., Moreno-Elola-Olaso, C., Rey, E., Locke III, G.R. & Rodriguez-Artalejo, F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population, 95
- Dietary fiber*, 245
- Dietary supplements*, 245
- Dignass, A. *see* Büning, C.
- Disease management*, 63
- Dixon, A. *see* Todd, J.A.
- Dominguez-Muñoz, E. *see* Gisbert, J.P.
- Donnelly, J.R. *see* Gremse, D.A.
- Dormann, H., Criegee-Rieck, M., Neubert, A., Egger, T., Levy, M., Hahn, E.G. & Brune, K. Implementation of a computer-assisted monitoring system for the detection of adverse drug reactions in gastroenterology, 303
- Double-blinded randomized controlled study*, 455
- Doxycycline*, 789
- Drug effects*, 679
- Drug safety*, 179, 679
- Drug-induced*, 391
- Drug-resistant mutants*, 323
- Dubois, R.W. *see* Graham, D.Y.
- Dubois, R.W., Melmed, G.Y., Henning, J.M. & Laine, L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy, 197
- Ducrotté, P. *see* Galmiche, J.P.
- Dulbecco, P. *see* Zentilin, P.
- Dupont, A.W. *see* Raines, D.L.
- Dwarakanath, D. *see* Rubin, G.P.
- Dyard, F. *see* Bouchnik, Y.
- Dyspepsia*, 233, 917, 1099
- Dysplasia*, 879
- Early response*, 339
- Economic evaluation*, 349
- Egger, T. *see* Dormann, H.
- El Ghoul, Z. *see* Louis, E.
- El-Serag, H.B., Aguirre, T., Kuebler, M. & Sampliner, R.E. The length of newly diagnosed Barrett's oesophagus and prior use of acid suppressive therapy, 1255
- El-Serag, H.B., Pilgrim, P. & Schoenfeld, P. Systematic review: natural history of irritable bowel syndrome, 861
- El-Serag, H.B. & Talley, N.J. Systematic review: the prevalence and clinical course of functional dyspepsia, 643
- Emerenziani, S. *see* Biancone, L.
- Emmanuel, A.V., Shand, A.G. & Kamm, M.A. Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response, 687
- Empirical trial*, 1123
- Endoscopic retrograde cholangiopancreatography*, 1153
- Endoscopy*, 989
- Enteral stent*, 901
- Epidemiological studies*, 497
- Epidemiology*, 233, 287, 1025, 1217
- Eradication*, 219
- Eradication predictors*, 407
- Eradication therapy*, 1181
- Erdmann, J., Lippl, F., Klose, G. & Schusdziarra, V. Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations, 1173
- Ernst, E. *see* Borrelli, F.
- Erythromycin*, 687
- Escobedo, S. *see* Chiba, N.

- Eslick, G.D., Howell, S.C., Hammer, J. & Talley, N.J. Empirically derived symptom sub-groups correspond poorly with diagnostic criteria for functional dyspepsia and irritable bowel syndrome. A factor and cluster analysis of a patient sample, 133  
*Esomeprazole*, 655, 1105  
*Etest*, 1315  
*Ethnic differences*, 765  
*Evidence based medicine*, 1235  
*Extrapyramidal reactions*, 379  
*Factor analysis*, 133  
*Faecal*, 923  
*Faecal continence*, 311  
*Faecal incontinence*, 829  
*Faeces*, 923  
*Failure of medical therapy*, 1079  
Fakhheri, H., Merat, S., Hosseini, V. & Malekzadeh, R. Low-dose furazolidone in triple and quadruple regimens for *Helicobacter pylori* eradication, 89  
Fallingborg, J. *see* Vilien, M.  
Fallone, C.A. *see* Barkun, A.N.  
Fan, S.-T. *see* Hui, C.-K.  
Fan, S.T. *see* Lam, C.-M.  
Fan, S.-T. *see* Poon, R.T.-P.  
Färkkilä, M.A. *see* Koivisto, T.T.  
Fass, R. *see* Bautista, J.  
*Fatty liver*, 537  
Feakins, R.M. *see* Langmead, L.  
Fellermann, K. *see* Herrlinger, K.R.  
Fennell, J.M. *see* Ho, G.T.  
Ferenci, P. Review article: diagnosis and current therapy of Wilson's disease, 157  
Ferrante, M. *see* Marchal, L.  
Fett, S.L. *see* Halder, S.L.S.  
Fickert, P. *see* Wenzl, H.H.  
Fina, D. *see* Biancone, L.  
Fine, D.R. *see* Treble, T.M.  
Fini, L. *see* Candelli, M.  
Fiocca, R. *see* Zentilin, P.  
Fiorentini, P. *see* Galmiche, J.P.  
Firpi, R.J., Tran, T.T., Flores, P., Nissen, N., Colquhoun, S., Shackleton, C., Martin, P., Vierling, J.M. & Poordad, F.F. Sirolimus-induced hyperlipidaemia in liver transplant recipients is not dose-dependent, 1033  
Fischer, C. *see* Herrlinger, K.R.  
*Fissure-in-anus*, 695  
*Fistula*, 295  
Fleig, W.E. *see* Herrlinger, K.R.  
Flores, P. *see* Firpi, R.J.  
Flourié, B. *see* Bouhnik, Y.  
Fong, C.Y. *see* Chan, A.O.O.  
Forbes, A. *see* Bloom, S.  
Fox, M., Thumshirn, M., Menne, D., Stutz, B., Fried, M. & Schwizer, W. The pathophysiology of faecal spotting in obese subjects during treatment with orlistat, 311  
*Fragmentation*, 545  
Francavilla, A. *see* De Francesco, V.  
Franciosi, S. *see* Angelico, M.  
Freeman, J.G. *see* Austin, A.S.  
Freston, J.W., Pilmer, B.L., Chiu, Y.-L., Wang, Q., Stolle, J.C., Griffin, J.S. & Lee, C.Q. Evaluation of the pharmacokinetics and pharmacodynamics of intravenous lansoprazole, 1111  
Fried, M. *see* Fox, M.  
Friis, S. *see* Norgård, B.  
Fullerton, H. *see* Bautista, J.  
*Functional colonic diseases*, 245  
*Functional dyspepsia*, 219, 631, 643, 797  
*Functional gastrointestinal disorders*, 133, 1235  
*Furazolidone*, 89  
Gabrielli, M. *see* Santarelli, L.  
*Gallbladder*, 797  
*Gallbladder motility*, 601  
*Gallstone formation*, 601  
Galmiche, J.-P. *see* Zerbib, F.  
Galmiche, J.P., Bruley Des Varannes, S., Ducrotté, P., Sacher-Huvelin, S., Vavasseur, F., Taccon, A., Fiorentini, P. & Homerin, M. Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers, 655  
Gambaro, C. *see* Zentilin, P.  
García-Monzón, C. *see* Apolinario, A.  
Gasbarrini, A. *see* Cammarota, G.  
Gasbarrini, A. *see* Candelli, M.  
Gasbarrini, A. *see* Cremonini, F.  
Gasbarrini, A. *see* Santarelli, L.  
Gasbarrini, G. *see* Cammarota, G.  
Gasbarrini, G. *see* Candelli, M.  
Gasbarrini, G. *see* Cremonini, F.  
Gasbarrini, G. *see* Santarelli, L.  
*Gastric accommodation*, 415, 1261  
*Gastric acid*, 1105  
*Gastric acid secretion*, 253, 1181  
*Gastric adenocarcinoma*, 841  
*Gastric barostat*, 1261  
*Gastric carcinoma*, 989  
*Gastric mucosal atrophy*, 1181  
*Gastric outflow obstruction*, 901  
*Gastric pH*, 655  
*Gastric sensitivity*, 415, 1261  
*Gastric tachyarrhythmia*, 583  
*Gastric tone*, 415  
*Gastric ulcer*, 989  
*Gastroesophageal reflux disease*, 463  
*Gastrointestinal bleeding*, 591  
*Gastrointestinal cancer*, 497  
*Gastrointestinal oncology*, 1, 191, 401, 771, 901, 981, 1159  
*Gastrointestinal physiology*, 39  
*Gastrointestinal prokinesia*, 379  
*Gastro-oesophageal reflux*, 95, 931  
Gene, E. *see* Gisbert, J.P.  
*General Practice*, 917  
Genschel, J. *see* Büning, C.

- Gentile, S. *see* Angelico, M.  
 GERD, 455, 463, 1041  
 Geremia, A. *see* Biancone, L.  
 Gessner, U. *see* Dammann, H.-G.  
 Giacobbe, A. *see* Mangia, A.  
 Giannini, E.G. & Testa, R. Letter to the Editors, 827  
 Gibson, J.A. *see* Green, J.R.B.  
 Gimona, A. *see* Kivitz, A.J.  
 Gisbert, J.P., Khorrami, S., Carballo, F., Calvet, X., Gene, E. & Dominguez-Muñoz, E. Meta-analysis: *Helicobacter pylori* eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer, 617  
 Gisbert, J.P., Trapero, M., Calvet, X., Mendoza, J., Quesada, M., Güell, M. & Pajares, J.M. Evaluation of three different tests for the detection of stool antigens to diagnose *Helicobacter pylori* infection in patients with upper gastrointestinal bleeding, 923  
*Glucocorticoid Receptor*, 47  
*Gluten-free*, 1277  
 Goddard, C.J.R. *see* Ho, G.T.  
 Goland, S. *see* Kaptan, K.  
 Goldthorpe, S. *see* Langmead, L.  
 Gorard, D.A. *see* Kitiyakara, T.  
 GORD, 253  
 Grace, E. *see* Chiba, N.  
 Graham, D.Y. *see* Chan, F.K.L.  
 Graham, D.Y., Laine, L. & Dubois, R.W. Letter to the Editors, 1323  
 Granström, M. *see* Wheeldon, T.-U.  
*Green tea*, 497  
 Green, J.R.B., Swan, C.H.J., Gibson, J.A., Kerr, G.D., Swarbrick, E.T. & Thornton, P.C. Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study, 435  
 Greinwald, R. *see* Herrlinger, K.R.  
 Gremse, D.A., Donnelly, J.R., Kukulka, M.J., Lloyd, E. & Lee, C. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe, 1211  
 Grieco, A. *see* Angelico, M.  
 Grieco, A. *see* Cammarota, G.  
 Griffin, J.S. *see* Freston, J.W.  
 Grob, R. *see* Krol, N.  
 Grønbæk, K. *see* Vilien, M.  
*Growth factors*, 1019  
*Growth/Development/Nutrition*, 245, 583, 1277  
 Güell, M. *see* Gisbert, J.P.  
*Guidelines*, 197  
 Guillemot, F. *see* Bouhnik, Y.  
 Gulsen, M. *see* Uygun, A.  
 Guslandi, M. *see* Brisinda, G.  
*H. pylori*, 253, 349, 993, 1181, 1309  
 Haaijer-Ruskamp, F. *see* Krol, N.  
 Hadziyannis, S.J. *see* Papatheodoridis, G.V.  
 Hahn, E.G. *see* Dormann, H.  
 Halder, S.L.S., Locke III, G.R., Talley, N.J., Fett, S.L., Zinsmeister, A.R. & Melton III, L.J. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study, 233  
 Halphen, M. *see* Brisinda, G.  
 Hammer, J. *see* Eslick, G.D.  
 Hammer, J. & Schmidt, B. Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough, 1105  
 Hanauer, S.B. *see* Sandborn, W.J.  
 Harb, G. *see* Jensen, D.M.  
 Haruma, K. *see* Kai, H.  
 Haugk, B. *see* Aithal, G.P.  
 Hauschmidt Juhl, H. *see* Meinecke-Schmidt, V.  
 Hawkey, C. *see* Kivitz, A.J.  
*HBsAg*, 771  
*HCC*, 771  
*HCV chronic hepatitis*, 331  
*Healing*, 359  
*Health economics*, 1247  
*Health service research*, 191, 1247  
*Heartburn*, 95, 463  
 Heikkilä, M. *see* Koivisto, T.T.  
*Helicobacter*, 841  
*Helicobacter pylori*, 89, 107, 219, 407, 789, 923, 1009, 1315  
 Henning, J.M. *see* Dubois, R.W.  
*Heparin*, 871  
*Hepatitis*, 323  
*Hepatitis C*, 1159  
*Hepatitis C virus*, 551  
*Hepatitis vaccination*, 715  
*Hepatocellular carcinoma*, 999, 1301  
*Hepatotoxicity*, 391  
 Herba, K. *see* Barkun, A.N.  
*Herbal*, 271  
*Herbal therapy*, 739  
 Herdman, C.R. *see* Schwartz, D.A.  
 Herrlinger, K.R., Fellermann, K., Fischer, C., kreisel, W., Deibert, P., Schoelmerich, J., Fleig, W.E., Ruhl, A., Reinshagen, M., Greinwald, R., Stange, E.F. & Schwab, M. Thioguanine-nucleotides do not predict efficacy of thioguanine in Crohn's disease, 1269  
 Hertervig, E. *see* Sturegård, E.  
*Hiatal hernia*, 663  
 Hiele, M. *see* Marchal, L.  
 Higgins, P.D.R., Davis, K.J. & Laine, L. Systematic review: the epidemiology of ischaemic colitis, 729  
*High dose lanzoprazole*, 1123  
 Hinterleitner, T.A. *see* Wenzel, H.H.  
 Ho, G.T., Mowat, C., Goddard, C.J.R., Fennell, J.M., Shah, N.B., Prescott, R.J. & Satsangi, J. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery, 1079  
 Ho, P. *see* Lam, C.-M.  
 Hoang, T.T.H. *see* Wheeldon, T.-U.

- Hoes, A.W. *see* Bijkerk, C.J.  
 Holt, H. *see* Langmead, L.  
 Holtmann, G. *see* Madisch, A.  
 Homerin, M. *see* Galimberti, J.P.  
 Horikawa, Y. *see* Shimatani, T.  
*Hormone replacement therapy*, 563  
*Hormones and Receptors*, 47, 687, 695, 797, 805  
*Hospital stay*, 63  
 Hosseini, V. *see* Fakheri, H.  
*Host factors*, 219  
 Hotz, J. *see* Madisch, A.  
 Houghton, L.A. *see* Calvert, E.L.  
 Howell, S.C. *see* Eslick, G.D.  
 Hu, P.J. *see* Xiong, L.S.  
 Hu, W.H.C. *see* Hui, C.-K.  
 Hu, W.H.C. *see* Wong, W.M.  
 Huang, J.Q. *see* Wong, W.M.  
 Huang, Y.-H. *see* Huo, T.  
 Huang, Y.-H. *see* Huo, T.-I.  
 Hui, C.-K., Liu, C.-L., Lai, K.-C., Chan, S.-C., Hu, W.H.C., Wong, W.-M., Cheung, W.W., Ng, M., Yuen, M.-F., Chan, A.O., Lo, C.M., Fan, S.-T. & Wong, B.C.Y. Outcome of emergency ERCP for acute cholangitis in patients 90 years of age and older, 1153  
 Hui, W.M. *see* Wong, W.M.  
*Human*, 889  
 Hungin, A.P.S. *see* Panter, S.J.  
 Hungin, A.P.S. *see* Rubin, G.P.  
 Hunter, M.M. & McKay, D.M. Review article: helminths as therapeutic agents for inflammatory bowel disease, 167  
 Huo, T., Huang, Y.-H., Wu, J.-C., Chiang, J.-H., Lee, P.-C., Chang, F.-Y. & Lee, S.-D. Comparison of transarterial chemoembolization and percutaneous acetic acid injection as the primary loco-regional therapy for unresectable hepatocellular carcinoma: a prospective survey, 1301  
 Huo, T.-I., Wu, J.-C., Huang, Y.-H., Chiang, J.-H., Lee, P.-C., Chang, F.-Y. & Lee, S.-D. Acute renal failure after transarterial chemoembolization for hepatocellular carcinoma: a retrospective study of the incidence, risk factors, clinical course and long-term outcome, 999  
 Hvenegaard, A. *see* Meineche-Schmidt, V.  
*HVPG measurement*, 571  
*Hyperhomocysteinaemia*, 107  
*Hyperlipidemia*, 1173  
*Hyperprolactinaemia*, 379  
 Iacobellis, A. *see* Mangia, A.  
*IBD*, 941  
*IBS visceral hypersensitivity*, 123, 271  
*ICAM-1*, 281  
 Ierardi, E. *see* De Francesco, V.  
 Iijima, K., Sekine, H., Koike, T., Imatani, A., Ohara, S. & Shimosegawa, T. Long-term effect of *Helicobacter pylori* eradication on the reversibility of acid secretion in profound hypochlorhydria, 1181  
 Iiritano, E. *see* Zentilin, P.  
*Ileal involvement*, 1073  
*Ileal mucosa*, 671  
*Ileocecal resection*, 1073  
 Imatani, A. *see* Iijima, K.  
*Immune deviation*, 167  
*Immunology and Microbiology*, 47, 89, 167, 511, 521, 551, 749, 1009, 1033, 1293  
*Immunosuppression*, 427  
*Incontinence*, 481  
*Inflammatory bowel disease*, 63, 755  
*Inflammatory disorders*, 47, 179, 427, 511, 521, 529, 551, 729, 739, 749, 755, 871, 1019, 1063, 1189, 1269  
*Infliximab*, 295  
*Infliximab therapy*, 1019  
*iNOS IL-6 gastrin*, 1309  
 Inoue, M. *see* Shimatani, T.  
*Insulin resistance*, 537  
*Integrated intragastric acidity*, 443  
*Interferon*, 339  
*Interferon- $\alpha$* , 25  
*Interleukin 6*, 671  
*Intestinal disorders*, 1, 47, 123, 179, 197, 233, 245, 263, 295, 311, 511, 671, 687, 695, 729, 739, 749, 755, 861, 901, 1009, 1025, 1063, 1079, 1235, 1277  
*Intestinal fibrosis*, 1019  
*Intestinal microflora*, 889  
*Intragastric pH*, 443  
*Intragastric pH > 4*, 113  
*Intravenous*, 1111  
*Iran*, 89  
*Iron deficiency anaemia*, 663  
*Irritable bowel syndrome*, 133, 263, 271, 1199, 1217  
 Irvine, E.J. *see* Bloom, S.  
 Isik, A.T. *see* Uygun, A.  
 Ito, M. *see* Kai, H.  
 Jacobsen, J. *see* Nørgård, B.  
 Jain, R. *see* Malik, A.H.  
 Jansen, J.B.M.J. *see* van Rossum, L.G.M.  
 Janssens, J. *see* Demarchi, B.  
 Jensen, D.M., Cotler, S.J., Lam, H., Harb, G. & Shillington, A. A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres, 69  
 Jess, T., Winther, K.V., Munkholm, P., Langholz, E. & Binder, V. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark, 287  
 Jewell, D.P. *see* Langmead, L.  
 Johns, C.E. *see* Newton, J.L.  
 Johnsen, S.P. *see* Nørgård, B.  
 Jonderko, K. *see* Mangel, A.W.  
 Kadayifci, A. *see* Uygun, A.  
 Kai, H., Ito, M., Kitadai, Y., Tanaka, S., Haruma, K. & Chayama, K. Chronic gastritis with expression of inducible nitric oxide

- synthase is associated with high expression of interleukin-6 and hypergastrinaemia, 1309
- Kamerling, I.M.C., Van Haarst, A.D., De Kam, M.L., Cohen, A.F., Masclee, A.A.M. & Burggraaf, J. Gallbladder volume as a biomarker for the motilin effect in healthy volunteers and patients with functional dyspepsia, 797
- Kamm, M.A. *see* Emmanuel, A.V.
- Kane, S.V. *see* Loftus Jr, E.V.
- Kang, J.Y., Dhar, A., Pollok, R., Leicester, R.J., Benson, M.J., Kumar, D., Melville, D., Neild, P.J., Tibbs, C.J. & Maxwell, J.D. Diverticular disease of the colon: ethnic differences in frequency, 765
- Kaptan, K., Beyan, C., Malnick, S., Goland, S., Rajendra, S. & Alahuddin, S. Letters to the Editors, 703
- Kasicka-jonderko, A. *see* Mangel, A.W.
- Katz, P.O. *see* Tutuian, R.
- Kaukinen, K. *see* Collin, P.
- Keefe, E.B. *see* Lin, O.S.
- Keefe, E.B. *see* Reiss, G.
- Kennedy, W. *see* Barkun, A.N.
- Kerr, G.D. *see* Green, J.R.B.
- Khorrami, S. *see* Gisbert, J.P.
- Killerich, S. *see* Bloom, S.
- Kitadai, Y. *see* Kai, H.
- Kitagawa, T. *see* Yamamoto, T.
- Kitiyakara, T., Bailey, D.M., McIntyre, A.S. & Gorard, D.A. Adenomatous colonic polyps are rare in ulcerative colitis, 879
- Kivitz, A.J., Nayiager, S., Schimansky, T., Gimona, A., Thurston, H.J. & Hawkey, C. Reduced incidence of gastroduodenal ulcers associated with lumiracoxib compared with ibuprofen in patients with rheumatoid arthritis, 1189
- Kling, K. *see* Büning, C.
- Klose, G. *see* Erdmann, J.
- Klotz, U. *see* Treiber, G.
- K-means*, 133
- Knottnerus, J.A. *see* Bijkerk, C.J.
- Koike, T. *see* Iijima, K.
- Koivisto, T.T., Rautelin, H.I., Voutilainen, M.E., Niemelä, S.E., Heikkinen, M., Sipponen, P.I. & Färkkilä, M.A. Primary *Helicobacter pylori* resistance to metronidazole and clarithromycin in the Finnish population, 1009
- k-ras*, 1225
- Kreisel, W. *see* Herrlinger, K.R.
- Krol, N., Wensing, M., Haaijer-Ruskamp, F., Muris, J.W.M., Numans, M.E., Schattenberg, G., Van Balen, J. & Grol, R. Patient-directed strategy to reduce prescribing for patients with dyspepsia in general practice: a randomized trial, 917
- Krüger, S. *see* Büning, C.
- Krupp, S. *see* Dammann, H.-G.
- Kuebeler, M. *see* El-Serag, H.B.
- Kukulka, M.J. *see* Gremse, D.A.
- Kumar, D. *see* Kang, J.Y.
- Kumar, K.S. *see* Malik, A.H.
- Kuroiwa, T. *see* Shimatani, T.
- Laboratory signals*, 303
- Ladabaum, U. *see* Mein, S.M.
- Laheij, R.J.F. *see* van Rossum, L.G.M.
- Lai, C.L. *see* Chan, A.O.O.
- Lai, K.-C. *see* Hui, C.-K.
- Lai, K.C. *see* Wong, W.M.
- Laine, L. *see* Dubois, R.W.
- Laine, L. *see* Graham, D.Y.
- Laine, L. *see* Higgins, P.D.R.
- Lam, C.L.K. *see* Wong, W.M.
- Lam, C.M. *see* Chan, A.O.O.
- Lam, C.-M., Chan, A.O.O., Ho, P., Ng, I.O.-L., Lo, C.M., Liu, C.L., Poon, R.T.P. & Fan, S.T. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients — implications for screening, 771
- Lam, H. *see* Jensen, D.M.
- Lam, K.F. *see* Wong, W.M.
- Lam, S.K. *see* Wong, W.M.
- Lamivudine*, 25, 323
- Langholz, E. *see* Bloom, S.
- Langholz, E. *see* Jess, T.
- Langmead, L., Feakins, R.M., Goldthorpe, S., Holt, H., Tsironi, E., De Silva, A., Jewell, D.P. & Rampton, D.S. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis, 739
- Langmead, L., Makins, R.J. & Rampton, D.S. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa *in vitro*, 521
- Lansoprazole*, 45, 1111, 1211
- Lassen, M.R. *see* Bloom, S.
- Lawson, M.J. *see* Tagore, K.S.
- Leandro, G. *see* Mangia, A.
- Lee, C. *see* Gremse, D.A.
- Lee, C.Q. *see* Freiston, J.W.
- Lee, J. *see* Chiba, N.
- Lee, K.-J., Vos, R. & Tack, J. Effects of capsaicin on the sensorimotor function of the proximal stomach in humans, 415
- Lee, P.-C. *see* Huo, T.
- Lee, P.-C. *see* Huo, T.-I.
- Lee, S.-D. *see* Huo, T.
- Lee, S.-D. *see* Huo, T.-I.
- Leicester, R.J. *see* Courtney, E.D.J.
- Leicester, R.J. *see* Kang, J.Y.
- Leiper, K. *see* Bloom, S.
- Lembo, T. *see* Schwetz, I.
- Leo, P. *see* Soncini, M.
- Leslie, W.D. *see* Bernstein, C.N.
- Leung, N.W.-Y. *see* Wong, V.W.-S.
- Levin, T.R. *see* Tagore, K.S.
- Levine, M.E., Muth, E.R., Williamson, M.J. & Stern, R.M. Protein-predominant meals inhibit the development of gastric tachyarrhythmia, nausea and the symptoms of motion sickness, 583
- Levy, M. *see* Dormann, H.
- Libby, G.W. *see* Castle, M.Z.D.
- Lin, O.S., Keefe, E.B., Sanders, G.D. & Owens, D.K. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C, 1159

- Lindsay, J.O., Andreyev, H.J.N., Vlavianos, P. & Westaby, D. Self-expanding metal stents for the palliation of malignant gastroduodenal obstruction in patients unsuitable for surgical bypass, 901
- Linear height*, 253
- Lipase*, 601
- Lipase inhibitor*, 1261
- Lipiodol*, 779
- Lippl, F. *see* Erdmann, J.
- Liu, C.-L. *see* Hui, C.-K.
- Liu, C.L. *see* Lam, C.-M.
- Liver biopsy*, 545
- Liver cirrhosis*, 999, 1301
- Liver descriptors*, 25, 79, 209, 401, 545, 551, 999, 1033, 1159, 1301
- Liver transplantation*, 157
- Lloyd, E. *see* Gremse, D.A.
- Lo Iacono, O. *see* Apolinario, A.
- Lo, C.M. *see* Hui, C.-K.
- Lo, C.M. *see* Lam, C.-M.
- Lochs, H. *see* Büning, C.
- Locke III, G.R. *see* Diaz-Rubio, M.
- Locke III, G.R. *see* Halder, S.L.S.
- Locke III, G.R., Yawn, B.P., Wollan, P.C., Melton III, L.J., Lydick, E. & Talley, N.J. Incidence of a clinical diagnosis of the irritable bowel syndrome in a United States population, 1025
- LODT*, 1211
- Loftus Jr, E.V., Kane, S.V. & Bjorkman, D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis, 179
- Lorente, R. *see* Apolinario, A.
- Louis, E., El Ghoul, Z., Vermeire, S., Dall'Ozzo, S., Rutgeerts, P., Paintaud, G., Belaiche, J., De Vos, M., Van Gossum, A., Colombel, J.-F. & Watier, H. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease, 511
- Lowson, D. *see* Bloom, S.
- Lucey, M.R. *see* Tome, S.
- Luckow, A. *see* Meineche-Schmidt, V.
- Lumiracoxib*, 1189
- Lydick, E. *see* Locke III, G.R.
- Mabisombi, A. *see* Brisinda, G.
- Madisch, A., Holtmann, G., Plein, K. & Hotz, J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial, 271
- Maggiore, G. *see* Sciveres, M.
- Magni (on behalf of the Ring Study Group), G. *see* Soncini, M.
- Mahida, Y.R. *see* Austin, A.S.
- Maintenance treatment*, 1147
- Majano, P.L. *see* Apolinario, A.
- Mäki, M. *see* Collin, P.
- Makins, R.J. *see* Langmead, L.
- Malekzadeh, R. *see* Fakheri, H.
- Malet, P.F. *see* Malik, A.H.
- Malfertheiner, P. *see* Treiber, G.
- Malik, A.H., Kumar, K.S., Malet, P.F., Jain, R., Prasad, P. & Ostapowicz, G. Correlation of percutaneous liver biopsy fragmentation with the degree of fibrosis, 545
- Malnick, S. *see* Kaptan, K.
- Mangel, A.W., Jonderko, K., Kasicka-Jonderko, A. & Blonska-Pajfrowska, B. Letters to the Editors, 141
- Mangia, A., Spinzi, G., Vuturo, O., Pazienza, V., Iacobellis, A., Piatelli, M., Giacobbe, A., Leandro, G., Piermanni, V., Minoli, G., Montalto, G. & Andriulli, A. Viral clearance in HCV viraemic patients with normal alanine aminotransferase after combination therapy: a controlled, open-labelled study, 331
- Manning criteria*, 1217
- Mansi, C. *see* Zentilin, P.
- Marangi, S. *see* De Francesco, V.
- Marchal, L., D'Haens, G., Van Assche, G., Vermeire, S., Noman, M., Ferrante, M., Hiele, M., Bueno De Mesquita, M., D'Hoore, A., Penninckx, F. & Rutgeerts, P. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study, 749
- Margiotta, M. *see* De Francesco, V.
- Maria, G. *see* Brisinda, G.
- Marniga, G. *see* Brisinda, G.
- Martin, P. *see* Firpi, R.J.
- Martino, A. *see* Cammarota, G.
- Masclée, A.A.M. *see* Kammerling, I.M.C.
- Mastracci, L. *see* Zentilin, P.
- Mathus-Vliegen, E.M.H., Van Ierland-Van Leeuwen, M.L. & Terpstra, A. Lipase inhibition by orlistat: effects on gall-bladder kinetics and cholecystokinin release in obesity, 601
- Matin, K. *see* Schwetz, I.
- Matsumoto, K. *see* Yamamoto, T.
- Maxwell, J.D. *see* Kang, J.Y.
- May, F.E.B. *see* Newton, J.L.
- Mayer, E.A. *see* Schwetz, I.
- McCormick, P.A. *see* O'Keeffe, C.
- McIntyre, A.S. *see* Kitiyakara, T.
- McKay, D.M. *see* Hunter, M.M.
- McLaughlin, J.K. *see* Nørgård, B.
- Median intragastric pH value*, 113
- Medical Decision Analysis*, 191
- Medical therapy*, 295, 511
- Medical treatment*, 953
- Medication toxicity*, 1033
- Mein, S.M. & Ladabaum, U. Serological testing for coeliac disease in patients with symptoms of irritable bowel syndrome: a cost-effectiveness analysis, 1199
- Meineche-Schmidt, V., Hauschildt Juhl, H., Østergaard, J.E., Luckow, A. & Hvenegaard, A. Costs and efficacy of three different esomeprazole treatment strategies for long-term management of gastro-oesophageal reflux symptoms in primary care, 907
- Melmed, G.Y. *see* Dubois, R.W.
- Melton III, L.J. *see* Halder, S.L.S.
- Melton III, L.J. *see* Locke III, G.R.
- Melville, D. *see* Kang, J.Y.
- Melville, D.M. *see* Courtney, E.D.J.
- Mendoza, J. *see* Gisbert, J.P.

- Menne, D. *see* Fox, M.  
 Merat, S. *see* Fakhri, H.  
*Meta-Analysis*, 631  
*Metformin*, 537  
*Methodology*, 631  
*Methotrexate*, 295  
*Methylated 6-thioguanine nucleotides*, 1269  
*Metronidazole*, 1009  
*MIC*, 1315  
 Michel, C. *see* Bouchnik, Y.  
*Microsatellite instability marker*, 1225  
 Middel, P. *see* Raddatz, D.  
 Miele, L. *see* Cammarota, G.  
 Minenna, M.F. *see* De Francesco, V.  
 Miner Jr, P., Wedel, M., Bane, B. & Bradley, J. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis, 281  
 Minić, M. *see* Brisinda, G.  
 Minoli, G. *see* Mangia, A.  
*Misoprostol*, 1051  
 Moayyedi, P. *see* Abraham, N.S.  
 Molnar, B. *see* Rusovics, A.  
*Monitoring*, 449  
 Moniz, C. *see* Pereira, S.P.  
 Moniz, C. *see* Trebble, T.M.  
 Mönnikes, H. *see* Stanghellini, V.  
 Montalto, G. *see* Mangia, A.  
*Morbidity*, 779  
 Moreno-Ela-Olaso, C. *see* Diaz-Rubio, M.  
 Morini, S. *see* De Francesco, V.  
*Motilin*, 797  
*Motility and nerve-gut interactions*, 95, 123, 271, 311, 415, 583, 601, 687, 695, 805, 861, 1025, 1235, 1261  
 Mowat, C. *see* Ho, G.T.  
 Mullee, M.A. *see* Trebble, T.M.  
*Multicenter study*, 63  
 Munakata, J. *see* Schwetz, I.  
 Munck, L.K. *see* Vilien, M.  
 Munkholm, P. *see* Jess, T.  
 Muris, J.W.M. *see* Bijkerk, C.J.  
 Muris, J.W.M. *see* Krol, N.  
 Muscatello, N. *see* De Francesco, V.  
*Mutation analysis*, 157  
 Mutth, E.R. *see* Levine, M.E.  
*Mycophenolate mofetil*, 427  
 Naliboff, B. *see* Schwetz, I.  
*Nausea*, 583  
 Nayiager, S. *see* Kivitz, A.J.  
*NCCP*, 1123  
 Nedrow, S.I. *see* Ward, E.M.  
 Neild, P.J. *see* Kang, J.Y.  
 Neubert, A. *see* Dormann, H.  
*Neurotensin*, 931  
 Neut, C. *see* Bouchnik, Y.  
 Newton, J.L., Johns, C.E. & May, F.E.B. Review article: the ageing bowel and intolerance to aspirin, 39  
 Ng, F.-H., Wong, B.C.-Y., Wong, S.-Y., Chen, W.-H. & Chang, C.-M. Clopidogrel plus omeprazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk — a single-blind, randomized controlled study, 359  
 Ng, I.O.-L. *see* Lam, C.-M.  
 Ng, M. *see* Hui, C.-K.  
 Niemelä, S.E. *see* Koivisto, T.T.  
 Nilsson, L.E. *see* Wheeldon, T.-U.  
 Nissen, N. *see* Firpi, R.J.  
 Nista, E.C. *see* Cammarota, G.  
 Nista, E.C. *see* Candelli, M.  
 Nista, E.C. *see* Santarelli, L.  
*Nocturnal acid breakthrough*, 655, 1105  
*Nocturnal gastric acid breakthrough (NAB)*, 113  
*NOD2*, 1073  
 Nolan, N. *see* O'Keefe, C.  
 Norman, M. *see* Marchal, L.  
*Nonalcoholic steatohepatitis*, 537  
*Non-cardiac chest pain*, 1123  
*Non-ulcer dyspepsia*, 133, 993  
 Nørgård, B., Pedersen, L., Jacobsen, J., Rasmussen, S.N. & Sørensen, H.T. The risk of congenital abnormalities in children fathered by men treated with azathioprine or mercaptopurine before conception, 679  
 Nørgård, B., Pedersen, L., Johnsen, S.P., Tarone, R.E., McLaughlin, J.K., Friis, S. & Sørensen, H.T. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study, 817  
 Nørregaard, P. *see* Vilien, M.  
*NSAIDs*, 197, 817, 1051  
 Numans, M.E. *see* Krol, N.  
*Nutrition*, 779, 1173  
 O'Keefe, C., Baird, A.W., Nolan, N. & McCormick, P.A. Cholestatic pruritus — the role of cutaneous mast cells and nerves, 1293  
 O'Morain, C. *see* Bloom, S.  
*Obesity*, 311, 601, 1173  
 Ockenga, J. *see* Büning, C.  
 O'Donohue, J. *see* Pereira, S.P.  
*Oesophagus*, 449  
*Oesophageal disorders*, 907  
*Oesophageal manometry*, 931  
*Oesophageal varices*, 571  
*Oesophageal / gastric / duodenal disorders*, 89, 95, 191, 197, 233, 463, 591, 601, 841, 1009, 1111, 1181, 1189, 1277  
 O'Flanagan, H. *see* Panter, S.J.  
 Ohara, S. *see* Iijima, K.  
 Ohning, G. *see* Schwetz, I.  
*On demand treatment*, 907  
*Oral syringe*, 1211  
*Orally disintegrating tablet*, 1211  
*Orlistat*, 311, 601, 1173  
 Orm, S. *see* Bloom, S.

- Ostapowicz, G. *see* Malik, A.H.  
*Osteoporosis*, 941  
*Østergaard*, J.E. *see* Meineche-Schmidt, V.  
*Outcome*, 981, 1079, 1153  
*Owens*, D.K. *see* Lin, O.S.  
*Ozgurtas*, T. *see* Uygun, A.
- p53*, 1225  
*Paintaud*, G. *see* Louis, E.  
*Pajares*, J.M. *see* Gisbert, J.P.  
*Palla*, G. *see* Sciveres, M.  
*Pallone*, F. *see* Biancone, L.  
*Pancreatic disorders*, 901  
*Panella*, C. *see* De Francesco, V.  
*Panter*, S.J., *O'Flanagan*, H., *Bramble*, M.G. & *Hungin*, A.P.S.  
 Empirical use of antisecretory drug therapy delays diagnosis of upper gastrointestinal adenocarcinoma but does not effect outcome, 981  
*Panzuto*, F., *Di Giulio*, E., *Capurso*, G., *Baccini*, F., *D'Ambra*, G., *Delle Fave*, G. & *Annibale*, B. Large hiatal hernia in patients with iron deficiency anaemia: a prospective study on prevalence and treatment, 663  
*Papatheodoridis*, G.V. & *Hadziyannis*, S.J. Review article: current management of chronic hepatitis B, 25  
*Parruti*, G. *see* Angelico, M.  
*Paternal drug exposure*, 679  
*Patient sample*, 133  
*Patient-directed strategy*, 917  
*Patients with persistently normal ALT*, 331  
*Pazienza*, V. *see* Mangia, A.  
*Pedersen*, L. *see* Norgård, B.  
*Peginterferon*, 551  
*Pelvic floor*, 481  
*Penninx*, F. *see* Marchal, L.  
*Pentoxifylline*, 79  
*Peptic ulcer*, 359  
*Peptic ulcer disease*, 993  
*Percutaneous injection*, 1301  
*Pereira*, S.P., *O'Donohue*, J., *Moniz*, C., *Phillips*, M.G., *Abraha*, H., *Buxton-Thomas*, M. & *Williams*, R. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a 1-year controlled trial, 563  
*Pérez*, C. *see* Apolinario, A.  
*Perianal disease*, 427  
*Perianal fistula*, 953  
*Perri*, F. *see* Rajendra, S.  
*Petritsch*, W. *see* Wenzl, H.H.  
*Petruzzello*, C. *see* Biancone, L.  
*pH*, 449  
*pH monitoring*, 1105  
*Pharmaceutical cost*, 993  
*Pharmacodynamics*, 1111  
*Pharmacogenetics*, 511  
*Pharmacokinetics*, 1111, 1211  
*Pharmacovigilance*, 303  
*Phillips*, M.G. *see* Pereira, S.P.
- Phuncarg*, D.C. *see* Wheeldon, T.-U.  
*Piattelli*, M. *see* Mangia, A.  
*Piche*, T. *see* Zerbib, F.  
*Piermanni*, V. *see* Mangia, A.  
*Pilgrim*, P. *see* El-Serag, H.B.  
*Pilmer*, B.L. *see* Freiston, J.W.  
*Pirozzi*, G. *see* Cammarota, G.  
*Plein*, K. *see* Madisch, A.  
*Pola*, P. *see* Santarelli, L.  
*Pollok*, R. *see* Kang, J.Y.  
*Poluzzi*, E. *see* Tonini, M.  
*Polyps*, 879  
*Poon*, R.T.P. *see* Lam, C.-M.  
*Poon*, R.T.-P., *Yu*, W.-C., *Fan*, S.-T. & *Wong*, J. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial, 779  
*Poordad*, F.F. *see* Firpi, R.J.  
*Population Based Study*, 1025  
*Portal hypertension*, 79  
*Pouchitis*, 281  
*Prasad*, P. *see* Malik, A.H.  
*Prebiotic*, 889  
*Prescott*, R.J. *see* Ho, G.T.  
*Primary biliary cirrhosis*, 563  
*Primary care*, 349, 529, 907  
*Pritchard*, D.M. & *Przemeck*, S.M.C. Review article: how useful are the rodent animal models of gastric adenocarcinoma? 841  
*Proctalgia*, 481  
*Profound hypochlorhydria*, 1181  
*Proton pump inhibition*, 591  
*Proton pump inhibitor(s)*, 443, 663, 907, 1041, 1051, 1099, 1105  
*Pruritus*, 1293  
*Przemeck*, S.M.C. *see* Pritchard, D.M.
- Quality of life*, 529, 1099, 1217  
*Quality of life assessment*, 455  
*Quesada*, M. *see* Gisbert, J.P.  
*Questionnaire*, 463
- Rabeprazole*, 113  
*Raddatz*, D., *Middel*, P., *Bockemühl*, M., *Benöhr*, P., *Wissmann*, C., *Schwörer*, H. & *Ramadori*, G. Glucocorticoid receptor expression in inflammatory bowel disease: evidence for a mucosal down-regulation in steroid-unresponsive ulcerative colitis, 47  
*Radiocontrast agent*, 999  
*Raines*, D.L., *Dupont*, A.W. & *Arguedas*, M.R. Cost-effectiveness of hepatic venous pressure gradient measurements for prophylaxis of variceal re-bleeding, 571  
*Rajendra*, S. *see* Kapitan, K.  
*Rajendra*, S., *Alahuddin*, S. & *Perri*, F. Letters to the Editors, 375  
*Ramadori*, G. *see* Raddatz, D.  
*Rampton*, D.S. *see* Langmead, L.  
*Randomised controlled trial*, 349, 889  
*Randomised trial*, 917

- Rao, S.S.C. *see* Tuteja, A.K.  
 Raskine, L. *see* Bouchnik, Y.  
 Rasmussen, S.N. *see* Nørgård, B.  
 Rautelin, H.I. *see* Koivisto, T.T.  
 Record, C.O. *see* Aithal, G.P.  
*Reflux*, 449, 463  
 Reinshagen, M. *see* Herrlinger, K.R.  
 Reiss, G. & Keefee, E.B. Review article: hepatitis vaccination in patients with chronic liver disease, 715  
*Relapse*, 671  
*Renal failure*, 999  
*Reoperation*, 1073  
*Resistance*, 789  
*Review*, 245  
*Review article*, 941  
 Rex, D.K. *see* Chen, S.C.  
 Rey, E. *see* Diaz-Rubio, M.  
*Rheumatoid arthritis*, 1189  
*Ribavirin*, 551  
 Richards, C.J. *see* Todd, J.A.  
 Riottot, M. *see* Bouchnik, Y.  
*Risk score*, 1079  
 Robinson, R.J. *see* Todd, J.A.  
 Rodriguez-Artalejo, F. *see* Diaz-Rubio, M.  
*Rofecoxib*, 755  
*Rome II criteria*, 1217  
 van Rossum, L.G.M., Laheij, R.J.F., Vleminckx, F., Jansen, J.B.M.J. & Verheugt, F.W.A. Health-related quality of life in patients with cardiovascular disease – the effect of upper gastrointestinal symptom treatment, 1099  
 Rubin, G.P., Hungin, A.P.S., Chinn, D.J. & Dwarakanath, D. Quality of life in patients with established inflammatory bowel disease: a UK general practice survey, 529  
 Ruhl, A. *see* Herrlinger, K.R.  
 Russo, A. *see* Borrelli, F.  
 Russo, F. *see* De Francesco, V.  
 Rutgeerts, P. *see* Louis, E.  
 Rutgeerts, P. *see* Marchal, L.  
 Ruzsovics, A., Molnar B. Tulassay Z. Review article: deoxyribonucleic acid-based diagnostic techniques to detect *Helicobacter pylori*, 1137  
 Ryder, S.D. *see* Austin, A.S.  
  
 Sabusco, G. *see* Angelico, M.  
 Sacher-Huvelin, S. *see* Galmiche, J.P.  
 Saleki, M. *see* Dammann, H.-G.  
 Sampliner, R.E. *see* El-Serag, H.B.  
 Sandborn, W.J., Hanauer, S.B. & Buch, A. Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers, 1089  
 Sanders, G.D. *see* Lin, O.S.  
 Santarelli, L., Gabrielli, M., Cremonini, F., Santoliquido, A., Candelli, M., Nista, E.C., Pola, P., Gasbarrini, G. & Gasbarrini, A. Atrophic gastritis as a cause of hyperhomocysteinaemia, 107  
 Santoliquido, A. *see* Santarelli, L.  
*Satiety*, 1261  
 Satsangi, J. *see* Ho, G.T.  
 Savarino, V. *see* Zentilin, P.  
 Schattenberg, G. *see* Krol, N.  
 Schimansky, T. *see* Kivitz, A.J.  
 Schmidt, B. *see* Hammer, J.  
 Schmidt, H.H.-J. *see* Büning, C.  
 Schoelmerich, J. *see* Herrlinger, K.R.  
 Schoenfeld, P. *see* El-Serag, H.B.  
 Schoenfeld, P. Systematic review: incidence of abdominal/pelvic surgery amongst patients using tegaserod in randomized controlled trials, 263  
 Schröder, O., Blumenstein, I., Schulte-Bockholt, A. & Stein, J. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine, 295  
 Schulte-Bockholt, A. *see* Schröder, O.  
 Schulz, H.-U. *see* Dammann, H.-G.  
 Schürer, M. *see* Dammann, H.-G.  
 Schusdziarra, V. *see* Erdmann, J.  
 Schwab, M. *see* Herrlinger, K.R.  
 Schwabe, M. *see* Treiber, G.  
 Schwartz, D.A. & Herdman, C.R. Review article: the medical treatment of Crohn's perianal fistulas, 953  
 Schwetz, I., Naliboff, B., Munakata, J., Lembo, T., Chang, L., Matin, K., Ohning, G. & Mayer, E.A. Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome, 123  
 Schwizer, W. *see* Fox, M.  
 Schwörer, H. *see* Raddatz, D.  
 Sciveres, M., Caprai, S., Palla, G., Ughi, C. & Maggiore, G. Effectiveness and safety of cyclosporin as therapy for autoimmune diseases of the liver in children and adolescents, 209  
*Screening*, 571, 1159, 1225  
*Secondary prophylaxis*, 571  
*Second-line medical therapy*, 1079  
 Sekine, H. *see* Iijima, K.  
 Sepulveda, A. *see* Cremonini, F.  
*Sequential therapy*, 407, 993  
*Severe acute pancreatitis*, 1153  
 Shackleton, C. *see* Firpi, R.J.  
 Shah, N.B. *see* Ho, G.T.  
 Shand, A.G. *see* Emmanuel, A.V.  
 Shillington, A. *see* Jensen, D.M.  
 Shimatani, T., Inoue, M., Kuroiwa, T. & Horikawa, Y. Rabeprazole 10 mg twice daily is superior to 20 mg once daily for nighttime gastric acid suppression, 113  
 Shimosegawa, T. *see* Iijima, K.  
 Silk, D.B.A. *see* Castle, M.Z.D.  
 Sinclair, P. *see* Chiba, N.  
*Single Dose PK*, 1089  
 Sipponen, P.I. *see* Koivisto, T.T.  
 Sjunnesson, H. *see* Sturegård, E.  
*Somatostatin analogue*, 123

- Soncini, M., Triossi, O., Leo, P. & Magni (on behalf of the Ring Study Group), G. Inflammatory bowel disease and hospital treatment in Italy: the RING multi-centre study, 63
- Sonnenberg, A. Personal view: going around in circles — circuitous medical management plans, 191
- Sonnenberg, A. Personal view: patient-physician discordance about benefits and risks in gastroenterology decision-making, 1247
- Sörberg, M. *see* Wheeldon, T.-U.
- Sørensen, H.T. *see* Nørgård, B.
- Spaggiari, P. *see* Zentilin, P.
- Spinzi, G. *see* Mangia, A.
- Sprue, 1199
- Staging, 391
- Strange, E.F. *see* Herrlinger, K.R.
- Stanghellini, V., Armstrong, D., Mönnikes, H. & Bardhan, K.D. Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire? 463
- Stark, M.E. *see* Ward, E.M.
- Steatosis, 391
- Stein, J. *see* Schröder, O.
- Stern, R.M. *see* Levine, M.E.
- Steroid resistance, 47
- Stolle, J.C. *see* Freston, J.W.
- Stool, 923
- Stopino, V. *see* De Francesco, V.
- Stroud, M.A. *see* Trebble, T.M.
- Study 031, 1089
- Sturegård, E., Hertervig, E., Sjunnesson, H. & Wadström, T. Letter to the Editors, 613
- Sturniolo, G.C. *see* Di Sabatino, A.
- Stutz, B. *see* Fox, M.
- Surgery, 829, 1079
- Surgical complications, 749
- Surveillance, 303
- Survival, 779, 1301
- Swan, C.H.J. *see* Green, J.R.B.
- Swarbrick, E.T. *see* Green, J.R.B.
- Symptoms, 219, 463
- Systematic Review, 631
- Taccoen, A. *see* Galmiche, J.P.
- Tack, J. *see* Demarchi, B.
- Tack, J. *see* Lee, K.-J.
- Tagore, K.S., Levin, T.R. & Lawson, M.J. Review article: the evolution to stool DNA testing for colorectal cancer, 1225
- Talley, N.J. *see* El-Serag, H.B.
- Talley, N.J. *see* Eslick, G.D.
- Talley, N.J. *see* Halder, S.L.S.
- Talley, N.J. *see* Locke III, G.R.
- Tam, J.S.-L. *see* Wong, V.W.-S.
- Tanaka, S. *see* Kai, H.
- Tarone, R.E. *see* Nørgård, B.
- Tarquini, L. *see* Angelico, M.
- Tegaserod, 263
- Tenatoprazole, 655
- Terpstra, A. *see* Mathus-Vliegen, E.M.H.
- Test and eradicate, 349
- Testa, R. *see* Giannini, E.G.
- Thalidomide, 79
- Third-line, 789
- Thomson, A.B.R. *see* Chiba, N.
- Thorell, L. *see* Collin, P.
- Thornton, P.C. *see* Green, J.R.B.
- Threshold analysis, 1247
- Thumshirn, M. *see* Fox, M.
- Thurston, H.J. *see* Kivitz, A.J.
- Tibbs, C.J. *see* Kang, J.Y.
- Timm, J. *see* Dammann, H.-G.
- Tissue transglutaminase antibody, 1199
- Todd, J.A., Richards, C.J., Dixon, A. & Robinson, R.J. Gastric ulcer and malignancy — is there a need for follow-up endoscopy? 989
- Tome, S. & Lucey, M.R. Review article: current management of alcoholic liver disease, 707
- Tonini, M., Cipollina, L., Poluzzi, E., Crema, F., Corazza, G.R. & De Ponti, F. Review article: clinical implications of enteric and central D<sub>2</sub> receptor blockade by antidopaminergic gastrointestinal prokinetics, 379
- Torz, M. *see* Dammann, H.-G.
- Tosti, A. *see* Angelico, M.
- Tosti, C. *see* Biancone, L.
- Tran, T.T. *see* Firpi, R.J.
- Transarterial, 779
- Transient lower oesophageal sphincter relaxations, 931
- Transplantation, 1033
- Trapero, M. *see* Gisbert, J.P.
- Treatment, 253, 271, 631, 789, 829
- Trebbe, T.M., Wootton, S.A., Stroud, M.A., Mullee, M.A., Calder, P.C., Fine, D.R., Moniz, C. & Arden, N.K. Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status, 1063
- Treiber, G., Schwabe, M., Ammon, S., Walker, S., Klotz, U. & Malfertheiner, P. Dyspeptic symptoms associated with *Helicobacter pylori* infection are influenced by strain and host specific factors, 219
- Triossi, O. *see* Soncini, M.
- Triple therapy, 407, 993, 1315
- Tsironi, E. *see* Langmead, L.
- Tulassay, Z. *see* Ruzsovics, A.
- Tumor necrosis factor-alpha, 295
- Tumour necrosis factor, 79
- Tuteja, A.K. & Rao, S.S.C. Review article: recent trends in diagnosis and treatment of faecal incontinence, 829
- Tutuiyan, R., Castell, D.O., Xue, S. & Katz, P.O. The acidity index: a simple approach to the measurement of gastric acidity, 443
- Tuzun, A. *see* Uygun, A.
- Ughi, C. *see* Sciveres, M.
- Ulcerative colitis, 179, 879, 1079
- Ulcers, 1051, 1189

- Umegae, S. *see* Yamamoto, T.  
*Uninvestigated dyspepsia*, 349  
*Upper gastrointestinal bleeding*, 817  
*Upper GI cancer*, 981  
*Utility function*, 1247  
 Uygun, A., Kadayifci, A., Isik, A.T., Ozgurtas, T., Deveci, S., Tuzun, A., Yesilova, Z., Gulsen, M. & Dagpal, K. Metformin in the treatment of patients with non-alcoholic steatohepatitis, 537
- Vaca*, 407  
 Vakil, N. Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease, 1041  
 Van Assche, G. *see* Marchal, L.  
 Van Balen, J. *see* Krol, N.  
 Van Gossum, A. *see* Louis, E.  
 Van Haarst, A.D. *see* Kamerling, I.M.C.  
 Van Ierland-Van Leeuwen, M.L. *see* Mathus-Vliegen, E.M.H.  
*Vanilloid receptor*, 415  
 Vavasseur, F. *see* Galmiche, J.P.  
 Veldhuizen Van Zanten, S.J.O. *see* Abraham, N.S.  
 Veldhuizen Van Zanten, S.J.O. *see* Chiba, N.  
 Verheugt, F.W.A. *see* van Rossum, L.G.M.  
 Vermeire, S. *see* Louis, E.  
 Vermeire, S. *see* Marchal, L.  
 Vierling, J.M. *see* Firpi, R.J.  
 Vigneri, S. *see* Zentilin, P.  
 Vilien, M., Dahlerup J.F., Munck L.K., Nørregaard P., Grønbæk K., Fallingborg J. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year, 1147
- Viral resistance*, 25  
*Virologic response*, 551  
*Virological response rate*, 331  
*Vitamin B12*, 107  
 Vlavianos, P. *see* Lindsay, J.O.  
 Vlemmix, F. *see* van Rossum, L.G.M.  
 Vos, R. *see* Demarchi, B.  
 Vos, R. *see* Lee, K.-J.  
 Voutilainen, M.E. *see* Koivisto, T.T.  
 Vuturo, O. *see* Mangia, A.
- Wadström, T. *see* Sturegård, E.  
 Wald, A. *see* Brisinda, G.  
 Wald, A. *see* Cheung, O.  
 Walker, S. *see* Treiber, G.  
 Wang, Q. *see* Freston, J.W.  
 Wang, W.A. *see* Xiong, L.S.  
 Ward, E.M., Devault, K.R., Bouras, E.P., Stark, M.E., Wolfsen, H.C., Davis, D.M., Nedrow, S.I. & Achem, S.R. Successful oesophageal pH monitoring with a catheter-free system, 449  
 Watier, H. *see* Louis, E.  
 Wedel, M. *see* Miner Jr, P.  
*Weight loss*, 1173  
 Wensing, M. *see* Krol, N.
- Wenzl, H.H., Hinterleitner, T.A., Aichbichler, B.W., Fickert, P. & Petritsch, W. Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome, 427  
 Westaby, D. *see* Lindsay, J.O.  
 Wheeldon, T.-U., Granström, M., Hoang, T.T.H., Phuncarg, D.C., Nilsson, L.E. & Sörberg, M. The importance of the level of metronidazole resistance for the success of *Helicobacter pylori* eradication, 1315  
 Whorwell, P.J. *see* Calvert, E.L.  
 Williams, R. *see* Pereira, S.P.  
 Williamson, M.J. *see* Levine, M.E.  
*Wilson disease*, 157  
 Winther, K.V. *see* Jess, T.  
 Wissmann, C. *see* Raddatz, D.  
*Withdrawal*, 1147  
 Wolfsen, H.C. *see* Ward, E.M.  
 Wollan, P.C. *see* Locke III, G.R.  
 Wong, B.C.Y. *see* Chan, A.O.O.  
 Wong, B.C.Y. *see* Hui, C.-K.  
 Wong, B.C.-Y. *see* Ng, F.-H.  
 Wong, B.C.Y. *see* Wong, W.M.  
 Wong, J. *see* Poon, R.T.-P.  
 Wong, M.L. *see* Wong, V.W.-S.  
 Wong, N.Y.H. *see* Wong, W.M.  
 Wong, S.-Y. *see* Ng, F.-H.  
 Wong, V.W.-S., Chan, H.L.-Y., Wong, M.L., Tam, J.S.-L. & Leung, N.W.-Y. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants 323  
 Wong, W.-M. *see* Hui, C.-K.  
 Wong, W.M., Lai, K.C., Hui, W.M., Lam, K.F., Huang, J.Q., Hu, W.H.C., Wong, N.Y.H., Lam, C.L.K., Xia, H.H.X., Chan, A.O.O., Lam, S.K. & Wong, B.C.Y. Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease, 455  
 Wootton, S.A. *see* Treble, T.M.  
 Wu, J.-C. *see* Huo, T.  
 Wu, J.-C. *see* Huo, T.-I.
- Xia, H.H.X. *see* Wong, W.M.  
 Xiong, L.S., Chen, M.H., Chen, H.X., Xu, A.G., Wang, W.A. & Hu, P.J. A population-based epidemiologic study of irritable bowel syndrome in South China: stratified randomized study by cluster sampling, 1217  
 Xu, A.G. *see* Xiong, L.S.  
 Xue, S. *see* Tutuian, R.
- Yamamoto, T., Umegae, S., Kitagawa, T. & Matsumoto, K. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse, 671  
 Yawn, B.P. *see* Locke III, G.R.  
 Yesilova, Z. *see* Uygun, A.  
*YMDD mutants*, 323

- Young screening, 771  
Yu, W.-C. *see* Poon, R.T.-P.  
Yuen, M.F. *see* Chan, A.O.O.  
Yuen, M.-F. *see* Hui, C.-K.
- Zaru, S. *see* Angelico, M.  
Zentilin, P., Mastracci, L., Dulbecco, P., Gambaro, C., Bilardi, C., Ceppa, P., Spaggiari, P., Iiritano, E., Mansi, C., Vigneri, S., Fiocca, R. & Savarino, V. Carditis in patients with gastro-oesophageal reflux disease: results of a controlled study based on both endoscopy and 24-h oesophageal pH monitoring, 1285  
Zerbib, F., Piche, T., Charles, F., Galmiche, J.-P. & Bruley des Varannes, S. SR 48692, a specific neuropeptid receptor antagonist, has no effect on oesophageal motility in humans, 931  
Zinc, 157  
Zinsmeister, A.R. *see* Halder, S.L.S.  
Zullo, A. *see* De Francesco, V.



